AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology ...

The Tremfya (trem-FYE-ah) ad starts with a woman in a dark room with ... are considered to have a major interaction with ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... company’s executive director and biosimilar commercial lead, Stephen Pagnotta, noted is ...

CVS Caremark—the largest PBM in the U.S.—removed Humira from most of its commercial lists of reimbursable drugs starting April 1. In its place, the PBM included the Humira-referenced ...

Analysts note that the market's concern over Humira's impact is fading, with AbbVie's management effectively addressing the issue each quarter. The company's ability to execute its commercial ...

Its Commercial Medicines Unit will then begin its procurement process for adalimumab, considering Humira as well as its biosimilar rivals. New contracts are then expected to be in place by ...

Humira (adalimumab), a popular immunosuppressive medication, and its 22 biosimilars are largely absent from the formularies of Cigna's Express Scripts, CVS Caremark and UnitedHealth Group's Optum Rx.

BSC provides pharmacy benefits for about 2.5 million Californians and processes about 40,000 prescriptions a year for Humira. Starting January 1, 2025, most BSC commercial members using Fresenius ...